Cargando…

Retrospective Analysis of Adoptive TIL Therapy plus Anti-PD1 Therapy in Patients with Chemotherapy-Resistant Metastatic Osteosarcoma

BACKGROUND: The pathological subtype of osteosarcoma is one of the most common malignant bone tumors. Notably, chemotherapy-resistant metastatic osteosarcoma has been reported to cause significant mortality and shows poor prognosis with the currently available multidisciplinary treatments. This stud...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Xiang, Wu, Junlong, Duan, Chunguang, Liu, Yingjie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7547340/ https://www.ncbi.nlm.nih.gov/pubmed/33062726 http://dx.doi.org/10.1155/2020/7890985

Ejemplares similares

Adoptive transfer of TILs plus anti-PD1 therapy: An alternative combination therapy for treating metastatic osteosarcoma
por: Wang, Chao, et al.
Publicado: (2020)

TILs and Anti-PD1 Therapy: An Alternative Combination Therapy for PDL1 Negative Metastatic Cervical Cancer
por: Yin, Huanhuan, et al.
Publicado: (2020)

Apatinib plus chemotherapy for non-metastatic osteosarcoma: a retrospective cohort study
por: Wang, Jiaqiang, et al.
Publicado: (2023)

Evaluating different adoption scenarios for TIL-therapy and the influence on its (early) cost-effectiveness
por: Lindenberg, Melanie, et al.
Publicado: (2020)

Modulation of intracellular kinase signaling to improve TIL stemness and function for adoptive cell therapy
por: Feng, Hao, et al.
Publicado: (2022)

Adoptive TIL in HPV-negative oral scca
por: Leidner, Rom, et al.
Publicado: (2015)

Anti-PD-1 therapy plus chemotherapy versus anti-PD-1 therapy alone in patients with high-risk chemorefractory or relapsed gestational trophoblastic neoplasia: a multicenter, retrospective study
por: Wang, Xiaoyu, et al.
Publicado: (2023)

Expressions of CD8+TILs, PD-L1 and Foxp3+TILs in stage I NSCLC guiding adjuvant chemotherapy decisions
por: Teng, Feifei, et al.
Publicado: (2016)

TIL therapy and anti-CTLA4: can they co-exist?
por: Forget, Marie-Andrée, et al.
Publicado: (2019)

Towards next‐generation TIL therapy: TILs enriched in neoepitope‐specific T cells
por: Arnaud, Marion, et al.
Publicado: (2023)

Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers
por: Caushi, Justina X., et al.
Publicado: (2021)

Radiation Plus Anti-PD-1 Therapy for NSCLC Brain Metastases: A Retrospective Study
por: Liao, Guixiang, et al.
Publicado: (2021)

Is there a role for rechallenge and reintroduction of anti-EGFR plus chemotherapy in later lines of therapy for metastatic colorectal carcinoma? A retrospective analysis
por: Karani, Amanda, et al.
Publicado: (2020)

High post‐chemotherapy TIL and increased CD4+TIL are independent prognostic factors of surgically resected NSCLC following neoadjuvant chemotherapy
por: Jia, Wenxiao, et al.
Publicado: (2023)

Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial
por: Xie, Lu, et al.
Publicado: (2020)

Cost-Effectiveness of Ipilimumab Plus Anti-PD-1 Therapy Versus Ipilimumab Alone in Patients With Metastatic Melanoma Resistant to Anti-PD-(L)1 Monotherapy
por: Peng, Ye, et al.
Publicado: (2021)

Adoptive TIL Transfer in the Adjuvant Setting for Melanoma: Long-Term Patient Survival
por: Khammari, Amir, et al.
Publicado: (2014)

Anti-PD-1 plus anti-angiogenesis combined with chemotherapy in patients with HER2-negative advanced or metastatic gastric cancer: a multi-institutional retrospective study
por: Xu, Tongpeng, et al.
Publicado: (2023)

Author Correction: Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers
por: Caushi, Justina X., et al.
Publicado: (2021)

Correction: Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial
Publicado: (2020)

Cell Therapy With TILs: Training and Taming T Cells to Fight Cancer
por: Kumar, Amrendra, et al.
Publicado: (2021)

Response to anti-PD1 therapy with nivolumab in metastatic sarcomas
por: Paoluzzi, L., et al.
Publicado: (2016)

Muramyl Tripeptide Plus Chemotherapy Reduces Metastasis in Non-Metastatic Osteosarcoma: A Single-Center Experience
por: Taçyıldız, Nurdan, et al.
Publicado: (2020)

Fewer tumour-specific PD-1(+)CD8(+) TILs in high-risk “Infiltrating” HPV(−) HNSCC
por: Xu, Ke, et al.
Publicado: (2020)

PD-L1 expression and presence of TILs in small intestinal neuroendocrine tumours
por: Lamarca, Angela, et al.
Publicado: (2018)

Genetic inference of immune responsiveness of melanoma cancer patients to TIL therapy
por: Sommariva, Michele, et al.
Publicado: (2013)

First‐line therapy of bevacizumab plus chemotherapy versus cetuximab plus chemotherapy for metastatic colorectal cancer patients with mucinous adenocarcinoma or mucinous component
por: Zhou, Yu‐Wen, et al.
Publicado: (2021)

Anti-PD-1 antibody monotherapy versus anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy in unresectable or metastatic mucosal melanoma: a retrospective, multicenter study of 329 Japanese cases (JMAC study)
por: Nakamura, Y., et al.
Publicado: (2021)

Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up
por: van den Berg, Joost H, et al.
Publicado: (2020)

Response to Anti-PD-1 Therapy in Metastatic Merkel Cell Carcinoma Metastatic to the Heart and Pancreas
por: Mantripragada, Kalyan, et al.
Publicado: (2015)

Deciphering Microenvironment of NSCLC based on CD8+ TIL Density and PD-1/PD-L1 Expression
por: Lin, Ziying, et al.
Publicado: (2019)

PD-1(T) TILs as a Predictive Biomarker for Clinical Benefit to PD-1 Blockade in Patients with Advanced NSCLC
por: Hummelink, Karlijn, et al.
Publicado: (2022)

Pre- and post-operative anti-PD-L1 plus anti-angiogenic therapies in mouse breast or renal cancer models of micro- or macro-metastatic disease
por: Wu, Florence T. H., et al.
Publicado: (2018)

Fysikkpris til Fanamann
Publicado: (1981)

Petabytes til folket
Publicado: (2005)

Goldilocks and the three TILs
por: Dada, Hannah, et al.
Publicado: (2022)

Predictive relevance of PD-L1 expression with pre-existing TILs in gastric cancer
por: Ju, Xiaoli, et al.
Publicado: (2017)

Classification of gallbladder cancer by assessment of CD8(+) TIL and PD-L1 expression
por: Lin, Jianzhen, et al.
Publicado: (2018)

Concordance, Correlation, and Clinical Impact of Standardized PD-L1 and TIL Scoring in SCCHN
por: De Keukeleire, Stijn Jeroen, et al.
Publicado: (2022)

Anti-PD-1 Therapy plus Chemotherapy and/or Bevacizumab as Second Line or later Treatment for Patients with Advanced Non-Small Cell Lung Cancer
por: Zhang, Fan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_gomp3nnmqbjifv3397ps26is1n